Form 4: BioLife Solutions Exec Sells Shares for Tax Obligations

Karen A. Foster, Chief Quality and Operations at BioLife Solutions, sold 419 shares of common stock to cover tax withholding obligations.

Summary

• Karen A. Foster, Chief Quality and Operations of BIOLIFE SOLUTIONS INC (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 419 shares of common stock.
• The sale occurred on October 9, 2025, at a price of $27.36 per share.
• The sale was executed under a Rule 10b5-1(c) trading plan, which became effective on January 3, 2023.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following this transaction, Karen A. Foster beneficially owns 193,253 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sale for tax obligations) under a pre-arranged plan, which is generally considered neutral in terms of company sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of January 3, 2023, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

This insider transaction is a routine event and does not provide specific insights into broader industry trends or competitive landscape for BioLife Solutions.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, pre-planned sale for tax purposes by an executive and not indicative of a change in company fundamentals or executive confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider stock sale by an executive to cover tax obligations related to restricted stock vesting. Such transactions are common and typically do not reflect a change in the company's operational performance or the executive's long-term outlook. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this report.

Keywords

BioLife Solutions, BLFS, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Tax Withholding, Restricted Stock